Abstract
Advances in the molecular biology of oncogenesis have established a key role for transcription factors in malignant transformation. In some cases the activity of the transcription factor itself is altered by mutation. In many other cases, the activity of the transcription factor is affected by mutations in upstream signaling or regulatory proteins. This review highlights four transcription factors - Stat3, Stat5, NF-kB, and HIF-1 - which are associated with cancer development. The evidence for the involvement of these factors in oncogenesis is reviewed. Further, we examine the efforts to specifically target these transcription factors for therapeutic intervention. Such strategies include using peptidomimetics, antisense oligonucleotides, small molecule inhibitors, and G-quartet oligonucleotides. Inhibition of transcription factor activity may occur at the level of activation, translocation, or DNA binding. Application of these approaches to in vitro and in vivo models of tumorigenesis is discussed.
Keywords: ap family, apoptosis, oncogenesis, stats, src-homology (sh), janus kinases (jaks), reporter gene assays, oligodeoxynucleotides
Current Pharmaceutical Design
Title: Targeting Transcription Factors for Cancer Therapy
Volume: 11 Issue: 22
Author(s): M. S. Redell and D. J. Tweardy
Affiliation:
Keywords: ap family, apoptosis, oncogenesis, stats, src-homology (sh), janus kinases (jaks), reporter gene assays, oligodeoxynucleotides
Abstract: Advances in the molecular biology of oncogenesis have established a key role for transcription factors in malignant transformation. In some cases the activity of the transcription factor itself is altered by mutation. In many other cases, the activity of the transcription factor is affected by mutations in upstream signaling or regulatory proteins. This review highlights four transcription factors - Stat3, Stat5, NF-kB, and HIF-1 - which are associated with cancer development. The evidence for the involvement of these factors in oncogenesis is reviewed. Further, we examine the efforts to specifically target these transcription factors for therapeutic intervention. Such strategies include using peptidomimetics, antisense oligonucleotides, small molecule inhibitors, and G-quartet oligonucleotides. Inhibition of transcription factor activity may occur at the level of activation, translocation, or DNA binding. Application of these approaches to in vitro and in vivo models of tumorigenesis is discussed.
Export Options
About this article
Cite this article as:
Redell S. M. and Tweardy J. D., Targeting Transcription Factors for Cancer Therapy, Current Pharmaceutical Design 2005; 11 (22) . https://dx.doi.org/10.2174/1381612054546699
DOI https://dx.doi.org/10.2174/1381612054546699 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemoresistance in Non-Small Cell Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Assessment of the Usefulness of the SEMA5A Concentration Profile Changes as a Molecular Marker in Endometrial Cancer
Current Pharmaceutical Biotechnology Nanomedical Applications of Amphiphilic Dendrimeric Micelles
Current Medicinal Chemistry High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets Multimodality Imaging of RNA Interference
Current Medicinal Chemistry Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Phytocompounds from the Medicinal and Dietary Plants: Multi-target Agents for Cervical Cancer Prevention and Therapy
Current Medicinal Chemistry Heterocyclic Curcumin Derivatives of Pharmacological Interest: Recent Progress
Current Topics in Medicinal Chemistry Skp2 Inhibitors: Novel Anticancer Strategies
Current Medicinal Chemistry Bioactive Compounds of <i>Polygonatum sibiricum</i> - Therapeutic Effect and Biological Activity
Endocrine, Metabolic & Immune Disorders - Drug Targets COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition
Current Medicinal Chemistry Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery